Nuvalent Reports Director Departure, New CMO Appointment

Ticker: NUVL · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1861560

Sentiment: neutral

Topics: management-change, executive-compensation

Related Tickers: NUVAL

TL;DR

Nuvalent's board sees a change with Dr. Evans out, Dr. Parkinson in as CMO, and exec comp details filed.

AI Summary

On June 9, 2025, Nuvalent, Inc. filed an 8-K to report changes in its board of directors and executive compensation. Specifically, the company announced the departure of director Dr. R. Brad Evans and the appointment of Dr. David R. Parkinson as Chief Medical Officer. The filing also details compensatory arrangements for certain officers.

Why It Matters

Changes in key leadership roles and executive compensation can signal shifts in company strategy or performance, impacting investor confidence and future operational direction.

Risk Assessment

Risk Level: medium — Changes in key executive and director positions can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

FAQ

Who has departed from Nuvalent's board of directors?

Dr. R. Brad Evans has departed from Nuvalent's board of directors.

Who has been appointed as the new Chief Medical Officer at Nuvalent?

Dr. David R. Parkinson has been appointed as the new Chief Medical Officer at Nuvalent.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is June 9, 2025.

What is Nuvalent's principal executive office address?

Nuvalent's principal executive office is located at One Broadway, 14th Floor, Cambridge, Massachusetts 02142.

What is Nuvalent's telephone number?

Nuvalent's telephone number is (857) 357-7000.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 by Dr. R. Brad Evans regarding Nuvalent, Inc. (NUVL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing